177 related articles for article (PubMed ID: 38816091)
1. Drug-induced Lung Disease in the Oncology Patient: From Cytotoxic Agents to Immunotherapy.
Shroff GS; Sheshadri A; Altan M; Truong MT; Erasmus LT; Vlahos I
Clin Chest Med; 2024 Jun; 45(2):325-337. PubMed ID: 38816091
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic therapy-induced pulmonary toxicity.
Sadowska AM; Specenier P; Germonpre P; Peeters M
Expert Rev Anticancer Ther; 2013 Aug; 13(8):997-1006. PubMed ID: 23984900
[TBL] [Abstract][Full Text] [Related]
3. Therapy-induced toxicity of the lungs: an overview.
Charpidou AG; Gkiozos I; Tsimpoukis S; Apostolaki D; Dilana KD; Karapanagiotou EM; Syrigos KN
Anticancer Res; 2009 Feb; 29(2):631-9. PubMed ID: 19331213
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic drug-induced lung injury.
Snyder LS; Hertz MI
Semin Respir Infect; 1988 Sep; 3(3):217-28. PubMed ID: 3055113
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
Willemsen AE; Grutters JC; Gerritsen WR; van Erp NP; van Herpen CM; Tol J
Int J Cancer; 2016 May; 138(10):2312-21. PubMed ID: 26452336
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review.
Lehne G; Lote K
Acta Oncol; 1990; 29(2):113-24. PubMed ID: 2185802
[TBL] [Abstract][Full Text] [Related]
7. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
Endo M; Johkoh T; Kimura K; Yamamoto N
Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary toxicity of antineoplastic drugs.
Willson JK
Cancer Treat Rep; 1978 Dec; 62(12):2003-8. PubMed ID: 87268
[TBL] [Abstract][Full Text] [Related]
9. [Pulmonary toxicity of drugs and thoracic irradiation in children].
Fauroux B; Clément A; Tournier G
Rev Mal Respir; 1996 Jul; 13(3):235-42. PubMed ID: 8765915
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced lung injury.
Erasmus JJ; McAdams HP; Rossi SE
Semin Roentgenol; 2002 Jan; 37(1):72-81. PubMed ID: 11987768
[TBL] [Abstract][Full Text] [Related]
11. High-resolution CT of drug-induced lung disease.
Erasmus JJ; McAdams HP; Rossi SE
Radiol Clin North Am; 2002 Jan; 40(1):61-72. PubMed ID: 11813820
[TBL] [Abstract][Full Text] [Related]
12. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
13. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
14. Drug induced interstitial lung disease in oncology phase I trials.
Yonemori K; Hirakawa A; Kawachi A; Kinoshita F; Okuma H; Nishikawa T; Tamura K; Fujiwara Y; Takebe N
Cancer Sci; 2016 Dec; 107(12):1830-1836. PubMed ID: 27685762
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.
Osawa M; Kudoh S; Sakai F; Endo M; Hamaguchi T; Ogino Y; Yoneoka M; Sakaguchi M; Nishimoto H; Gemma A
Int J Clin Oncol; 2015 Dec; 20(6):1063-71. PubMed ID: 25967287
[TBL] [Abstract][Full Text] [Related]
16. Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.
Terbuch A; Tiu C; Candilejo IM; Scaranti M; Curcean A; Bar D; Estevez Timon M; Ameratunga M; Ang JE; Ratoff J; Minchom AR; Banerji U; de Bono JS; Tunariu N; Lopez JS
Clin Cancer Res; 2020 Sep; 26(18):4805-4813. PubMed ID: 32332017
[TBL] [Abstract][Full Text] [Related]
17. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
Nakao S; Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Respir Med; 2020 Oct; 172():106131. PubMed ID: 32911136
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary complications of cancer therapy.
Wesselius LJ
Compr Ther; 1999 May; 25(5):272-7. PubMed ID: 10390656
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.
Jagieła J; Bartnicki P; Rysz J
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924827
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary toxicity of antineoplastic therapy.
Kreisman H; Wolkove N
Semin Oncol; 1992 Oct; 19(5):508-20. PubMed ID: 1411649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
